Clearwater Capital Advisors’s ImmunityBio IBRX Stock Holding History

Clearwater Capital Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.28M	Hold	717,524	–	–	0.46%	34
2026 Q1	$5.5M	Sell	717,524 -127,560	-15%	-$873K	0.44%	35
2025 Q4	$1.67M	Sell	845,084 -1,335	-0.2%	-$3.02K	0.14%	57
2025 Q3	$2.08M	Hold	846,419	–	–	0.18%	54
2025 Q2	$2.23M	Hold	846,419	–	–	0.2%	52
2025 Q1	$2.55M	Hold	846,419	–	–	0.25%	50
2024 Q4	$2.17M	Buy	846,419 +363,870	+75%	+$1.52M	0.21%	55
2024 Q3	$1.8M	Hold	482,549	–	–	0.17%	59
2024 Q2	$3.05M	Buy	482,549 +39,250	+9%	+$259K	0.32%	45
2024 Q1	$2.38M	Hold	443,299	–	–	0.25%	52
2023 Q4	$2.23M	Buy	443,299 +48,700	+12%	+$153K	0.25%	51
2023 Q3	$667K	Hold	394,599	–	–	0.08%	69
2023 Q2	$1.1M	Buy	394,599 +77,448	+24%	+$219K	0.13%	63
2023 Q1	$577K	Buy	317,151 +131,240	+71%	+$408K	0.07%	83
2022 Q4	$943K	Hold	185,911	–	–	0.12%	71
2022 Q3	$924K	Buy	185,911 +600	+0.3%	+$2.73K	0.13%	78
2022 Q2	$689K	Buy	185,311 +37,420	+25%	+$150K	0.09%	81
2022 Q1	$830K	Buy	147,891 +7,340	+5%	+$45K	0.1%	81
2021 Q4	$855K	Sell	140,551 -7,340	-5%	-$55.1K	0.09%	89
2021 Q3	$1.44M	Buy	147,891 +75,865	+105%	+$835K	0.17%	65
2021 Q2	$1.03M	Hold	72,026	–	–	0.12%	75
2021 Q1	$1.71M	Buy	72,026 +37,971	+111%	+$984K	0.21%	59
2020 Q4	$454K	Buy	+34,055	New	+$328K	0.06%	105

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearwater Capital Advisors's IBRX Position: Q2 2026 in Review

Clearwater Capital Advisors held its ImmunityBio (IBRX) position steady in Q2 2026 at 717,524 shares worth $6.28M. The position accounts for 0.46% of the portfolio, ranked #34.

Clearwater Capital Advisors first reported a position in IBRX in Q4 2020 and has held it in 23 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Clearwater Capital Advisors held 717,524 shares of ImmunityBio worth $6.28M as of Q2 2026.
Clearwater Capital Advisors left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.46% of Clearwater Capital Advisors's portfolio in Q2 2026, its #34 holding.
Clearwater Capital Advisors first reported a position in ImmunityBio in Q4 2020 and has held it in 23 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Clearwater Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.